Chemicals

Amyris to Acquire Sweet-Protein Specialist Oobli

The deal pairs Amyris' strain engineering and fermentation manufacturing scale, including its expanded Barra Bonita plant, with Oobli's brazzein, monellin and thaumatin ingredient platform.

Kavya SridharNovember 16, 20265 min read0 views

A fermentation tank linked by piping to a lab bench where gloved hands examine a dish of pale protein powder next to a cluster of small berries.

Amyris, Inc., the Emeryville, Calif.-based biomanufacturing company, has announced that it will acquire Oobli Inc. of Davis, Calif., a sweet-protein developer whose fermentation-derived ingredients are used by food and beverage brands to reduce sugar without sacrificing taste.

The transaction is intended to combine Amyris' scientific and manufacturing capabilities with Oobli's expertise in protein fermentation. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its fermentation facility in Barra Bonita, Brazil, and represents a strategic commercial and technology expansion that accelerates its position in protein- and peptide-based solutions across end markets.

Oobli's portfolio to benefit first

Oobli's commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform. Over the past decade the company has refined a fermentation process for producing sweet proteins that occur naturally in rare fruits and berries grown near the equator. According to Oobli, these proteins are the first of their kind in the sugar-reduction category: they are hundreds to thousands of times sweeter than sugar, bind directly to sweet-taste receptors, and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes.

The portfolio comprises Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins, known scientifically as brazzein, monellin and thaumatin. They hold FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor. Oobli positions them for sugar reduction across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery, as consumer awareness of metabolic health continues to grow.

Executive views

Chief executive Kathy Fortmann described Oobli as a commercial and technology platform that complements Amyris' own. Oobli, she said, is positioned to change how sweetness makes it to market, and Amyris intends to bring its commercial scale and resources to accelerate that effort. Combining Oobli's protein expertise with Amyris' strain engineering, manufacturing scale and commercial capabilities could broaden its reach in food and beverage, personal care, flavor and fragrance, and agriculture.

Oobli chief executive Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment, and pointed to the breakthroughs achieved over the past decade. Joining Amyris, she said, gives Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.

Fortmann added that biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform gives brands a way to address sweet taste, sugar reduction and clean label at the same time.

Timing and continuity

The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored uninterrupted as Oobli's sweet-protein portfolio expands within the company.